AIRS

Airsculpt Technologies Inc
NASDAQHEALTHCAREMEDICAL CARE FACILITIES

Key Statistics

Market Cap
$330.86M
P/E Ratio
EPS
$-0.17
Beta
2.37
52W High
$12.00
52W Low
$1.51
50-Day MA
$4.82
200-Day MA
$4.13
Dividend Yield
Profit Margin
-7.39%
Forward P/E
PEG Ratio

About Airsculpt Technologies Inc

Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$151.84M
Gross Profit (TTM)$100.31M
EBITDA$7.51M
Operating Margin-4.58%
Return on Equity-12.60%
Return on Assets-1.60%
Revenue/Share (TTM)$2.40
Book Value$1.42
Price-to-Book3.24
Price-to-Sales (TTM)2.18
EV/Revenue2.5
EV/EBITDA410.32
Quarterly Earnings Growth (YoY)200.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$70.55M
Float$14.96M
% Insiders43.06%
% Institutions66.04%

Historical Volatility

HV 10-Day
54.42%
HV 20-Day
49.62%
HV 30-Day
49.53%
HV 60-Day
81.41%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($6.25 target)
2
Hold

Latest News

AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions

HONG KONG & SEOUL, South Korea--(BUSINESS WIRE)--AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical's next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) ac.

Business Wire6/16/2026Neutral
AirSculpt Technologies Announces Participation in Upcoming Investor Conferences

MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced that the Company will participate in upcoming investor conferences.

GlobeNewsWire5/27/2026Neutral
AirSculpt Technologies Q1 Earnings Call Highlights

AirSculpt Technologies NASDAQ: AIRS reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and continued debt reduction. Get AirSculpt Technologies alerts:Sign UpQ1 results: flat revenue, positive same-center sales, and margin expansion Chief Executive Officer Yogi Jashnani said the company “stabilized revenue year-over-year and delivered positive same-center sales for the first time in over two years,” while also expanding gross margin.

MarketBeat5/8/2026Positive
AirSculpt Technologies Reports First Quarter Fiscal 2026 Results

MIAMI BEACH, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the first quarter ended March 31, 2026.

GlobeNewsWire5/8/2026Neutral
AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results

MIAMI BEACH, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2026 financial results before market open on Friday, May 8, 2026, to be followed by a conference call on the same day at 8:30 a.m.

GlobeNewsWire5/1/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AIRS and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026